LeUprolide + Cholinesterase Inhibition to Reduce Neurologic Decline in Alzheimer’s

LUCINDA is a clinical research trial to determine whether leuprolide (Eligard, an injectable medication) can slow or prevent decline in thinking abilities and functioning in women with mild cognitive impairment or Alzheimer’s disease who are also taking a cholinesterase inhibitor such as donepezil (Aricept).

What does the study involve?
If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form. There will be approximately eight study visits spread out over one year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (leuprolide or placebo) four times over one year.

Key eligibility
- Women over age 65
- Diagnosed with mild cognitive impairment or Alzheimer’s disease
- Taking a cholinesterase inhibitor medication such as donepezil (Aricept)
- Participants must have a study partner (friend, family member or caregiver) who can accompany them to all study visits
- Detailed eligibility will be reviewed with the study team

Learn more about the LUCINDA Trial. Contact:
Maggie Chilsen
Clinical Research Coordinator
608-263-2704
mchilsen@clinicaltrials.wisc.edu
adrc.wisc.edu/lucinda

STUDY LEADERSHIP
Craig Atwood, PhD
University of Wisconsin–Madison
Madison, WI

Tracy Butler, MD
Weill Cornell Medicine
New York, NY

James Galvin, MD
University of Miami
Miami, FL

LUCINDA is supported by a grant from the National Institutes of Health
ClinicalTrials.gov: NCT03649724